Pharma companies face declining profits as the lenalidomide opportunity fades, impacting future growth and margins.
Dr. Reddy's Laboratories (NYSE:RDY) reported a “resilient performance” in its fiscal third quarter of FY26, with revenue growth and steady profitability despite what management described as ...
Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of ...
Move comes even as pricing pressure and regulatory complexity continue to weigh on global pharmaceutical markets.
Our current focus remains on tirzepatide in terms of being the best‑in‑class molecule,” said Achin Gupta, Cipla’s Managing ...
Consolidated net profit of drugmaker Dr. Reddy’s Laboratories declined more than 15% to ₹1,189.6 crore for the December quarter from ₹1,404.2 crore a year earlier on the back of multiple factors, ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced the launch of mesalamine 800 mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results